| Section       | Item | Checklist description                                                                 | Reported on Page Number/Line Number | Reported on Section/Paragraph |
|---------------|------|----------------------------------------------------------------------------------------|-------------------------------------|------------------------------|
| Title         | 1    | The diagnosis or intervention of primary focus followed by the words “case series”       | Page1/Line1                         | Title                        |
| Key Words     | 2    | 2 to 5 key words that identify diagnoses or interventions in this case series, including "case report" or "case series". | Page3/Line46-47                    | Key words                    |
| Abstract      | 3a   | Introduction—What is unique about this case series and what does it add to the scientific literature? | Page2/Line22-26                     | Abstract                     |
|               | 3b   | Methods—describe what was done, how and when was it done and by whom.                   | Page2/Line27-30                     | Abstract                     |
|               | 3c   | Results—what was found.                                                                 | Page2/Line31-39                     | Abstract                     |
|               | 3d   | Conclusion—What is the main take-away lesson(s)? What have we learned and what does it mean? | Page2-3/Line40-45                   | Abstract                     |
| Introduction  | 4    | Explain the scientific background and rationale for the case series.                    | Page3/Line49-65                     | Introduction/Paragraph1      |
| Methods       | 5a   | Registration and ethics—                                                                | Page3-4/Line67-75                   | Methods/Paragraph2           |
|               | 5a.1 | State the research registry number in accordance with the declaration of Helsinki - “Every research study involving human subjects must be registered in a publicly accessible database” (this can be obtained from: ResearchRegistry.com or ClinicalTrials.gov or ISRCTN). |                                    |                              |
|               | 5a.2 | State whether ethical approval was passed.                                              |                                    |                              |
|               | 5a.3 | Provide the patient consent form too.                                                   |                                    |                              |
|               | 5b   | Study design—state the study is a case series and whether prospective or retrospective in design, whether single or multi-center and whether cases are consecutive or non-consecutive. | Page3-4/Line67-75                   | Methods/Paragraph2           |
|               | 5c   | Setting - describe the setting(s)and nature of the institution in which the patient was managed; academic, community or private practice setting? Location(s), and relevant dates, including periods of recruitment, exposure, follow-up, and data collection. | Page3-4/Line67-75                   | Methods/Paragraph2           |
|               | 5d   | Participants—                                                                          | Page3-4/Line67-75                   | Methods/Paragraph2           |
|               | 5d.1 | Describe the relevant characteristics of the participants (history, comorbidities, tumor staging, smoking, etc.). |                                    |                              |
|               | 5d.2 | State any eligibility (inclusion/exclusion) criteria and the sources and methods of selection of participants. |                                    |                              |
| 5e | Intervention—types of intervention (such as pharmacologic, surgical, preventive, self-care) deployed and reasoning behind treatment offered. Pharmacological therapies should include formulation, dosage, strength, route and duration. | Page3-4/Line67-75 | Methods/Paragraph2 |
| 5f | Follow up—describe length and methods of follow-up. | Page3-4/Line67-75 | Methods/Paragraph2 |
| Results | 6a | Participants—reports numbers involved and their characteristics (comorbidities, tumor staging, smoking, etc.). | Page4-5/Line77-113 | Results/Paragraph3-5 |
| | 6b | Any changes in the interventions during the course of the case series (how has it evolved, been tinkered with, what learning occurred, etc.) together with rationale and a diagram if appropriate. | Page4-5/Line77-113 | Results/Paragraph3-5 |
| | 6c | Outcomes and follow-up—Clinician assessed and patient-reported outcomes (when appropriate) should be stated with inclusion of the time periods at which assessed. Relevant photographs/radiological images should be provided. e.g. 12-month follow-up. | Page4-5/Line77-113 | Results/Paragraph3-5 |
| | 6d | Where relevant—intervention adherence/compliance and tolerability (how was this assessed). Describe loss to follow-up (express as a percentage) and any explanations for it. | Page4-5/Line77-113 | Results/Paragraph3-5 |
| | 6e | Complications and adverse or unanticipated events. | Page4-5/Line77-113 | Results/Paragraph3-5 |
| Discussion | 7a | Summarize key results. | Page5-8/Line115-175 | Discussion/Paragraph6-9 |
| | 7b | Discussion of the relevant literature, implications for clinical practice guidelines. How do outcomes compare with established therapies and the prevailing gold standard? Generate a hypothesis if possible. | Page5-8/Line115-175 | Discussion/Paragraph6-9 |
| | 7c | Strengths and limitations of the study. | Page5-8/Line115-175 | Discussion/Paragraph6-9 |
| | 7d | The rationale for any conclusions. | Page5-8/Line115-175 | Discussion/Paragraph6-9 |
| Conclusion | 8a | State the key conclusions from the study. | Page8/Line177-182 | Conclusion/Paragraph10 |
| | 8b | State what needs to be done next, further research with what study design. | Page8/Line177-182 | Conclusion/Paragraph10 |

Article information: http://dx.doi.org/10.21037/jp-20-433

*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.*